Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 280033650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,319.74 | 108.00 | -0.25% |
| FTSE 100 | 8,810.47 | 0.57 | -0.01% |
| HKSE | 23,860.80 | 46.17 | -0.19% |
| NASDAQ | 19,298.45 | 162.04 | -0.83% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 5,939.30 | 31.51 | -0.53% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.69 | 1.59 | 0.05% |